MRI

Size: px

Start display at page:

Download "MRI"

すずりいなおか
7 years ago
Views:

2 MRI % 1.8%

3 ,360 8, ,770 3, ,224 20, ,542 1, ,743 3, ,999 5, ,882 18,565 1,683 51,570 52, ,630 14, ,142 2, ,372 10, ,069 1, ,705 4, ,215 1,350 4, ,703 5,370 3,238 2,132 2,845 5,313 2,468 13,182 16,882 3,700 51,570 52, ,361 8, ,770 3, ,224 20, ,281 33, ,374 2, ,907 31, ,832 14, ,023 4, ,909 11, ,649 2, ,726 33,569 1,157 3,819 2,091 1,728 26,004 23,913 2,091 29,823 26,004 3, ,650 67, ,805 62,346 3,541 8,845 5,180 3,665 16,979 21,274 4,295 13,182 16,882 3,700 3,502 4, ,629 88,800 4, ,450 17,693 2,243 10,833 13,278 2,445 4,617 4, ,002 7, , ,000 2,730 5,150 2,420 1,828 1, ,452 25,178 2,726 ) 12 92,000 89,626 2,374 29,823 26,004 3,819 84,629 88,800 4,171

4 , , % % M (200) H % 88.1% % 91.7% % 59.2% % 89.6% % 93.0% % 64.7% % 84.1% % 97.4% % 55.7% % 79.1% % 82.9% % 58.5% % 90.4% % 94.4% % 74.2% % 90.5% ( 87.4%) % 94.4% ( 92.6%) % 55.7% ( 54.5%) %

5 (%) (%) ,949 5, ,713 1, (%) (%) ,187 44, ,478 3, ,187 44, TCC International SOS

6 DIC 523 1/3 2/

8 English Language Study and Work Experience Programme Prof. Maurice Wright

9 literature

10 2000 (Section of Surgical Sciences, University of Sheffield, Northern General Hospital Trust, Sheffield, UK) BOAJOA

12 14 OB 12 OB OB 41 OB

13 A B C A 23 B 8 C 32 5/23 Nature 22 Nature 215 URAT URAT1 URAT1

14 life?) M.A. Hediger Nature News and Views (Gateway to a long NGO OSCE 427 OSCE(Ob- jective Structured Clinical Examination, OSCE OSCE 1) ) 2) :0015: OSCE 6) 44 OSCE 3) 4 4) 9

15 940 SP 10 1) 4) SP 5) OSCE 6 ) 23 OSCE 5 5 BSL 5 1 OSCE 1 2 2) 3) SP

16 OSCE E akagi@ kyorin-u.ac.jp OSCE

17 in

18 B1 4F Q 14 3F 4F WY B1 3 1 NLM WY WY 4F 4F AV M3F 3F NLM 2F B2F Z 1F B1F NDC A MB2F B1 BN B2 BN 14

19 M M M M61 M7 32 M

20 10 7 KRL 3 6 No KRL KRL KRL KRL KR 3 ADL QOL

21 ADL QOL :1517: , ,400 0 (A) 5,000 1,500 (A) 5,500 1,650 (B) 5,400 0 (B) 4,800 0 (B) 2,300 0 LAT1 4F2 CD98 SOD Innate immunity (B) 6,800 0 (C) (C) (C) (C) 1,000 0 (C) (C) (C) ECM (C) (C) 1,000 0 (C) 1,400 0 (C) 1,700 0

22 (C) 1,100 0 (C) 1,800 0 (C) LAT1 (C) 1,100 0 in vitro (C) 1,200 0 gdt 2 (C) 1,200 0 (C) 1,800 0 T FucT/CLA (C) 1,100 0 (C) 1,600 0 (C) 1,300 0 (C) 1,800 0 TRAIL (C) Spreading depression (C) 1,600 0 (C) (C) 2,100 0 (C) 2,700 0 (C) 2,200 0 (C) 2,200 0 (C) 1,800 0 (C) 2,400 0 Tissue Engineering HLA Th1Th ,100 0 (B) (B) (B) ,100 0 (B) (B) 1,000 0 (B) 1,100 0 (B) (B) (B) (B) (B) (B) , ,000 0 hoat1 T Buerger LAT1 T 1, ,700 0 Acticon neosphincter 1, ,500 0

23 (1) (1) (2) (2) (3) (3) (4) (1) 13 (1) 13 (2) 3 (2) 2 (3) (1) 2 (1) EndourologyESWL

24 NET NET ,800

25 50, ,000,000 2,000,000 1,000,000 () 1,000,000 1,000,000 () 100,000 1,000, ,000 50,000 1,000, ,500,000 1,000,000 56,000, , ,000, ,000 1 PCR 1 7 4,010, , ,000

26 A NICUGCU C 2 3C A 2 5A A 2 5A B C 2 3C

障害者職域拡大カリキュラム研究会中間報告書構成案

障害者職域拡大カリキュラム研究会中間報告書構成案 3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16